Literature DB >> 2231336

Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity.

A Haj-Yehia1, M Bialer.   

Abstract

Valpromide (VPD) and valnoctamide (VCD) are two isomers which are aliphatic amides derived from short fatty acids that possess anticonvulsant activity. Our previous studies with VPD, VCD, and other related compounds showed that the biotransformation of these amides to their respective homologous acids is the key issue in their possessing pharmacological activity. In this study, we explored the structure--pharmacokinetic relationships of the following five isomers or analogues of VPD: diisproprylacetamide (DID), diallylacetamide (DAD), octanamide (OAD), ethylisobutylacetamide (EID), and dimethylbutylacetamide (DBD). In addition, the anticonvulsant activity of these compounds was evaluated and compared with that of VPD and VCD. No plasma levels of OAD could be detected after its iv administration. Octanamide (OAD) was very rapidly metabolized to its homologous acid, octanoic acid (OAA). Octanamide (OAD) was different from the other four amides investigated, having a high clearance (due to metabolic processes in the blood) and possessing the least anticonvulsant activity. All of the other amides were stable in blood and showed similar pharmacokinetic parameters. Unlike the other amides, DID and VCD did not metabolize to their respective homologous acids due to the fact that they had a substituted beta position in their aliphatic side chain. Our study showed that, despite similarities in the chemical structures of the amides investigated, significant differences were observed in their pharmacokinetics and in the fraction of the amide (fm) biotransformed to its homologous acid. These differences in fm values may, therefore, account for the observed differences in the respective pharmacological activities, in general, and in the extent of the anticonvulsant activity, in particular, of the amides.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2231336     DOI: 10.1002/jps.2600790814

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.

Authors:  M Bialer; S Hadad; B Kadry; A Abdul-Hai; A Haj-Yehia; J Sterling; Y Herzig; B Yagen
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

2.  Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.

Authors:  Ilan Winkler; Simcha Blotnik; Jakob Shimshoni; Boris Yagen; Marshall Devor; Meir Bialer
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 3.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

4.  2D and 3D QSAR analysis of some valproic acid metabolites and analogues as anticonvulsant agents.

Authors:  T Netzeva; I Doytchinova; R Natcheva
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

5.  Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.

Authors:  M Levi; B Yagen; M Bialer
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

6.  Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.

Authors:  F Pisani; A Fazio; C Artesi; G Oteri; E Spina; T Tomson; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

7.  Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.

Authors:  A Haj-Yehia; S Hadad; M Bialer
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

Review 8.  Can we develop improved derivatives of valproic acid?

Authors:  M Bialer; A Haj-Yehia; K Badir; S Hadad
Journal:  Pharm World Sci       Date:  1994-02-18

9.  Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.

Authors:  Nina Isoherranen; H Steve White; Brian D Klein; Michael Roeder; José H Woodhead; Volker Schurig; Boris Yagen; Meir Bialer
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

Review 10.  Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.

Authors:  H Nau; H Siemes
Journal:  Pharm Weekbl Sci       Date:  1992-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.